Andrzej Nowakowski

TL;DR: HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines, according to this largest assessment of HPV genotypes to date.

TL;DR: Combined data from HPV-DNA and p16(INK4a) testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV, indicating that HPV contribution in invasive vulvar cancer has probably been overestimated.

TL;DR: In Europe, HPV16 predominates in both HG‐CIN and ICC, whereas HPV18/45 are associated with a low median age of ICC, and the need for primary prevention of HPV16/18‐45‐related cervical lesions is supported.

TL;DR: HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3 and the most common type detected, HPV16 was the most frequently type detected in both precancerous and cancerous lesions.

TL;DR: Since the great majority of CGN are HPV16/18/45‐positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies and special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV.